erlotinib hydrochloride has been researched along with amiloride in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (amiloride) | Trials (amiloride) | Recent Studies (post-2010) (amiloride) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 7,584 | 339 | 788 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | amiloride (IC50) |
|---|---|---|---|
| Urokinase-type plasminogen activator | Homo sapiens (human) | 4.7 | |
| Urokinase-type plasminogen activator | Mus musculus (house mouse) | 2.3 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 3.909 | |
| Sodium/hydrogen exchanger 1 | Rattus norvegicus (Norway rat) | 1 | |
| Amiloride-sensitive sodium channel subunit alpha | Homo sapiens (human) | 0.776 | |
| Sodium/hydrogen exchanger 2 | Oryctolagus cuniculus (rabbit) | 1 | |
| Acid-sensing ion channel 3 | Homo sapiens (human) | 4.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, WM; Li, T; Shao, TF; Xiang, XQ; Yang, HY; Zhao, B; Zheng, YT | 1 |
1 other study(ies) available for erlotinib hydrochloride and amiloride
| Article | Year |
|---|---|
Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Topics: Amiloride; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Resting Phase, Cell Cycle; Signal Transduction; Time Factors | 2015 |